ZA200306638B - Use of certain steroids for treatment of blood cell deficiencies. - Google Patents
Use of certain steroids for treatment of blood cell deficiencies. Download PDFInfo
- Publication number
- ZA200306638B ZA200306638B ZA200306638A ZA200306638A ZA200306638B ZA 200306638 B ZA200306638 B ZA 200306638B ZA 200306638 A ZA200306638 A ZA 200306638A ZA 200306638 A ZA200306638 A ZA 200306638A ZA 200306638 B ZA200306638 B ZA 200306638B
- Authority
- ZA
- South Africa
- Prior art keywords
- optionally substituted
- ester
- independently
- thioether
- scn
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 31
- 210000000601 blood cell Anatomy 0.000 title claims description 8
- 230000007812 deficiency Effects 0.000 title claims description 8
- 150000003431 steroids Chemical class 0.000 title description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 120
- -1 sulfite ester Chemical class 0.000 claims description 110
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 96
- 150000001875 compounds Chemical class 0.000 claims description 74
- 150000002148 esters Chemical class 0.000 claims description 66
- 150000003568 thioethers Chemical class 0.000 claims description 63
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 56
- 150000007970 thio esters Chemical class 0.000 claims description 56
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 53
- 229920001542 oligosaccharide Polymers 0.000 claims description 52
- 150000002482 oligosaccharides Chemical class 0.000 claims description 51
- 229920000642 polymer Polymers 0.000 claims description 51
- 125000000623 heterocyclic group Chemical group 0.000 claims description 50
- 150000002772 monosaccharides Chemical class 0.000 claims description 49
- 150000001408 amides Chemical class 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 125000002252 acyl group Chemical group 0.000 claims description 43
- 125000003441 thioacyl group Chemical group 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 40
- 125000003107 substituted aryl group Chemical group 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 38
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 36
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 26
- 208000024891 symptom Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 18
- 239000002777 nucleoside Substances 0.000 claims description 18
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 206010073306 Exposure to radiation Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 125000003003 spiro group Chemical group 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 150000003555 thioacetals Chemical class 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 10
- 150000001241 acetals Chemical class 0.000 claims description 10
- 230000002411 adverse Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000003111 delayed effect Effects 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 230000002503 metabolic effect Effects 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 6
- 206010043554 thrombocytopenia Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 210000000440 neutrophil Anatomy 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 208000004235 neutropenia Diseases 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 230000008629 immune suppression Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 11
- 229910004727 OSO3H Inorganic materials 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 150000008134 glucuronides Chemical group 0.000 claims 3
- 229910003849 O-Si Inorganic materials 0.000 claims 2
- 229910003872 O—Si Inorganic materials 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 229930182480 glucuronide Natural products 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000004449 DNA Virus Infections Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000009341 RNA Virus Infections Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 206010040799 Skin atrophy Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004129 fatty acid metabolism Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000036281 parasite infection Effects 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 230000028993 immune response Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 10
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000036952 cancer formation Effects 0.000 description 7
- 231100000504 carcinogenesis Toxicity 0.000 description 7
- 230000011132 hemopoiesis Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000029662 T-helper 1 type immune response Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229960002847 prasterone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010911 splenectomy Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- ZYIWVQVHPNIGTE-CMKOHOQOSA-N (5R,8R,9S,10S,13S,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,16,17-tetrol Chemical compound OC1C[C@@H]2CC([C@@H]3[C@H](CC[C@@]4(C(C(C[C@H]43)O)O)C)[C@]2(CC1)C)O ZYIWVQVHPNIGTE-CMKOHOQOSA-N 0.000 description 1
- DBJXJRIEZQPLSN-DXWCMRTCSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,7,16,17-tetrol Chemical compound C1C(O)CC[C@]2(C)[C@H]3CC[C@](C)(C(C(O)C4)O)[C@@H]4[C@@H]3C(O)C=C21 DBJXJRIEZQPLSN-DXWCMRTCSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- XMRPGKVKISIQBV-BJMCWZGWSA-N 5alpha-pregnane-3,20-dione Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 XMRPGKVKISIQBV-BJMCWZGWSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- AURFZBICLPNKBZ-SYBPFIFISA-N brexanolone Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-SYBPFIFISA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES
[0001] The invention relates to methods to make or use compounds, such as 16a- bromo-3B-hydroxy-5a-androstane-17-one (16a-bromoepiandrosterone or hereafter "BrEA”) 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrostane, 3,17-dihydroxy-16- haloandrostane, methyl 2,3 4-trihydroxy-1-0-(7,17-dioxoandrost-5-ene-3p-yl)--D- glucopyranosiduronate and related compounds. The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia and neutropenia.
[0002] Methods to prepare dehydroepiandrosterone ("DHEA") and other steroids and their biological properties have been described, see, e.g., U.S. patent numbers 2833793, 2911418,3148198, 3471480, 3976691, 4268441,4427649, 4542129, 4666898, 4956355, 5001119,5043165, 5077284, 5028631, 5110810,5157031,5162198, 5175154, 5277907, 5292730,5296481, 5372996, 5387583, 5407684,5424463, 5461042, 5478566, 5506223, 56518725,5527788, 5527789, 5532230, 5559107, 5562910, 5583126, 5585371, 5587369, 5591736,5593981, 5610150, 5635496, 5641766,5641768, 5656621, 5660835, 5686438, 5696106,5700793, 5707983, 5709878, 5710143,5714481, 5728688, 5736537, 5744462, 5753237,5756482, 5776921, 5776923, 5780460,5795880, 5798347, 5798348, 5804576, 5807848,5807849,5811418, 5824313, 5824668,5824671,5827841, 5837269, 5837700, 5843932,5846963, 5859000, 5872114 and 5872147;German patent numbers 2035738 and 2705917; PCT publication numbers WO 95/21617, WO 97/48367, WO 98/05338, WO 98/50040, WO 98/50041, WO 98/58650; European publication number 0020029; ER. Glazier, J. Org. Chem. 1962 27:2937-2938, Ben-David, et al., Proc. Soc.
Expt. Biol. Med. 1967 125:1136-1140, Coleman et al., Diabetes 1982 31:830, Oertel, et al.,
J. Steroid Biochem. 1972 3:493-496, Pashko, et al., Carcinogenesis 1981 2:717-721,
Schwartz et al., Nutr. Cancer 1981 3:46-53; Dyner et al., J. Acquired Immune Deficiency } Syndromes 1993 6:459-465; A.A. Afanasii and Y.A. Titov, Total Steroid Synthesis, Plenum
Press, New York, 1970, see, e.g., p 1-304. . [0003] The use DHEA and other steroids in various applications have been described, e.g., U.S. patent numbers 5869090, 5863910, 5856340, 5824668, 5804576, 5753237, 5714481,5709878, 5407684, 5206008, 5077284,4978532, 4898694, 4542129,
3711606 and 3710795.U.S. patent 4956355 and PCT publication number WO 97/48367, have described the use of certain steroid compounds to treat certain virus or bacterial infections, such as human immunodeficiency virus (“HIV”) infection.
[0004] Various biological effects and/or metabolic conversions of steroid compounds . 5 have also been described, e.g., Batta et al., J. Biol. Chem. 1986 25:127-133, Belli et al.,
Liver 1991 11:162-169, Bhattacharjee et al., Anal. Biochem. 1992 201:233-236, Blake et al.,
Int. J. Peptide Protein Res. 1982 20:97-101, 1986 25:127-133, Bonaventura, Am. J. Obstet.
Gynecol. 1978 131:403-409, Bucala et al., J. Steroid Biochem. 1986 25:127-133, Carey et al., Biochem. 1981 20:3637-3648, Chen et al., Carcinogenesis 1999 20:249-254, Chen et al, Carcinogenesis 1998 19:2187-2193, Chow et al., Antisense Res. Dev. 1994 4:81-86,
Citro et al., Dis. Colon Rectum 1994 37(2 Suppl):S127-S132, Cleary, Proc. Soc. Exp. Biol.
Med. 1991 196:8-16, Cleary, Int. J. Biochem. 1990 22:205-210, Crawford et al., Lab. Invest. 1994 71:42-51, Danenberg etal., Antimicrob. Agents Chemother. 1992 36:2275-2279,
Dotzlaw et al., Cancer Res. 1999 59:529-532, Falany et al., J. Steroid Biochem. Mol. Biol. 1994 48:369-375, Faredin et al., J. Investigative Dermatol. 1969 52:357-361, Galigniana et al., Mol. Pharmacol. 1999 55:317-323, Goto et al., J. Chromatogr. 1983 276:289-300, Grenot
Biochem. 1992 31:7609-7621, Hofbauer et al., Life Sci. 1999 64:671-679, Huijghebaert et al., J. Lipid Res. 1986 27:742-752, Hurd et al., Oncogene 1999 18:1067-1072, lida et al., J.
Lipid Res. 1995 36:628-638, Jellinck et al., Steroids 1967 10:329-346, Jonsson et al., J.
Pediatr. Gastroenterol. Nutr. 1995 20:394-402, Kalimi et al, Mol. Cell. Biochem. 1994 131:99-108, Kramer et al., J. Biol. Chem. 1994 269:10621-10627, LaRochelle et al., Steroids 1984 43: 209-217, Liao et al., Carcinogenesis 1998 19:2173-2180, Lillienau etal., J. Clin.
Invest. 1992 89:420-431, Loria, Psychoneuroendocrinology 1997 22:5103-S108, Luscher et al Mol. Immunol. 1983 20:1099-1105, Manna et al., J. Biol. Chem. 1999 274:5909-5918,
Marschall et al., J. Biol. Chem. 1989 264:12989-12993, Medh et al., Cancer Res. 1998 15:3684-3693, Mohan et al., Steroids 1992 57:244-247, Munoz de Toro et al., J. Steroid
Biochem. Mol. Biol. 1998 67:333-339, Padgett et al., J. Neuroimmunol. 1998 84:61, Padgett etal, Ann. N.Y. Acad. Sci. 1995 774:323, Padgett et al., J. Immunol. 1994 153:1544-1552,
Pashko et al., Carcinogenesis 1984 5:463-466, Pashko et al., Carcinogenesis 1981 2.717,
Petrylak et al,, J. Clin. Oncology 1999 17:958-967, Podesta et al., Steroids 1996 61.622-626,
Regelson et al., Ann. N.Y. Acad. Sci. 1994 719:564, Schmassmann et al., Gastroenterology . 1993 104:1171-1181,Schmassmann et al., Hepatology 1990 11:989-996, Schreiber et al.,
Lancet 353:459-461, Schreiber, Neth. J. Med. 1998 53:524-31, Schwartz et al., Cancer Res. ] 1988 48:4817, Shahidi et al., Biochem. Biophys. Res. Commun. 1999 254559-565, Steer et al., Ann. Rheum. Dis. 1998 57:732-737, Suzuki et al., Steroids 1998 63:672-677, Suzuki et al., Steroids 1996 61:296-301, Swaan et al., Bioconjugate Chem. 1997 8:520-525, Tang et al, Anticancer Drug Res. 1998 13:815-824, Thomas et al., J. Steroid Biochem. 1986 25:103- 108, Utsumi et al., Cancer Res. 1999 59:377-381, Vanden Heuvel, J. Nutr. 1999 129(2S
Suppl.):575S-580S, Wang et al., Endocrinology 1998 139:3903-3912,Wong et al., J. Biol.
Chem. 1999 274:5443-5453, Xie et al., Endocrinology 1999 140:219-227, Yen et al., Lipids 1977 12:409-413, Zackheim et al., Arch. Dermatology 1998 134:949-954, Zhang et al.,
Biochim. Biophys. Acta 1991 1096:179-186, Zhu et al., Carcinogenesis 1988 19:2101-21 06.
[0005] Mammalian immune responses to infections or other conditions are often characterized by responses mediated by different effector cell populations. In some situations, helper T cells designated Th1 in the murine system, facilitate immune effector functions that are typically dominated by celi-mediated responses. in other cases, helper T cells designated Th2 cells facilitate immune effector functions that are typically dominated by humoral responses. A vigorous Th1 response is usually desirable to help clear infections or to slow the progression of an infection. When a subject's immune response is biased fo, or dominated by, a Th2-type response, the cytokines associated with the Th2 response tend to suppress the immune system's capacity to mount a vigorous Th1 response at the same time. The converse is also generally true. When mammalian immune responses begin to result in an increasing Th2 response, the Th1 response to the same condition tends to weaken. Insufficient Th1 responses may be associated with progression of some infections or other conditions, see, e.g., M. Clerici and G.M. Shearer, Immunol. Today 14:107-111, 1993; M. Clerici and G.M. Shearer, Immunol. Today 15:575-681, 1994. The invention provides compounds and compositions useful to enhance Th1 immune responses.
[0006] Hemopoiesis or hematopoiesis is the formation and development of the various types of blood cells and their progenitor cells. Mature cells are found in circulation or tissues such as the lymph nodes or the thymus. Many of the stem cells that give rise to mature forms reside in the bone marrow, although some may circulate in the blood for some time. Clinical blood cell deficiencies such as thrombocytopenia, neutropenia orerythropenia can arise from causes such as impaired hemopoiesis or abnormal loss or destruction of mature or immature blood cells.
[0007] Thrombocytopenia ("TP"), abnormally low platelet counts, can arise from impaired platelet production, sequestration of platelets in the spleen or abnormal loss of circulating platelets. Impaired produdion can result from causes such as chemotherapies or
A radiation therapies. Abnormal loss of circulating platelets is often associated with autoreactive antibodies that bind to platelets and reduce their life span. These underlying . causes give rise to the various clinical forms of TP, such as autoimmune neonatal TP, immune thrombocytopenic purpra, radiation induced TP, chemotherapy induced TP and amegakaryocitic TP.
[0008] A number of treatment options are available and the selection of a treatment typically depends on the source of the disorder and its severity. Treatments include } administering one or more of glucocorticoid steroids (e.g., prednisone, prednisolone), human
IgG antibodies, anti-Rh(D)" antibodies for Rh(D)" patients, an androgen such as danazol, } 5 vinca alkaloids (e.g., vincristine, vinblastine), thrombopoietin and immunosuppresants (e.g., azathioprine, cyclophosphamide). Splenectomy is also indicated, for example when first line treatments fail. The goal of treatment is typically to increase platelet counts to 20,000 mm™ or more typically to at least about 50,000 mm™ and to maintain these levels.
[0009] Although the treatment options to increase platelet levels are generally known, they usually have a number of drawbacks. For example, infusion of IgG antibodies is not always effective and the treatment is relatively expensive. Other treatments, such as prednisone are also not always effective and they typically are discontinued or tapered off after several weeks due to toxicity or unwanted side effects. Splenectomy, which is relatively expensive and invasive, is also not always effective.
[0010] The sources of thrombocytopenia and treatment options have been described. See, e.g., Hematology - Basic Principles and Practice, 3" edition, R. Hoffman,
E.J. Benz Jr. et al., editors, Churchill Livingstone, New York, 2000 (see, e.g., Chapters 126- 129 and 131 at pages 2096-2154 and 2172-2186), PCT publication WO 200035466.
[0011] Neutropenia ("NP"), is considered to exist clinically when neutrophils drop to below a level considered normal. NP can arise from impaired production of neutrophil precursors or mature neutrophils, movement of neutrophils from the circulation to tissue, abnormal circulating neutrophil loss or a combination of these causes. Impaired neutrophil production can be acquired from, e.g., treatment with a cytotoxic or cytostatic drug, chemotherapy, radiation therapy or an autoimmune response. The abnormal loss of circulating neutrophils in autoimmunity is associated with autoreactive antbodies that bind to the cells and reduce their life span. These underlying causes give rise to the various clinical forms of NP, such as postinfectious NP, drug-induced NP, autoimmune NP, or chronic idiopathic NP.
[0012] The sources of NP and treatment options have been described. See, e.g.,
Hematology - Basic Principles and Practice, 3" edition, R. Hoffman, E.J. Benz Jr. et al., editors, Churchill Livingstone, New York, 2000 (see, e.g., Chapters 19, 41, 51,79, 134 and . 137 at pages 297-331, 720-762, 939-979, 1443-1500, 2220-2248 and 2257-2263).
[0013] The use of 3p-hydroxyandrost-5-ene-17-one, 3,17 p-dihydroxyandrost-5-ene . and other steroids to modulate immune functions or to stimulate myelopoiesis has been described, see, e.g., M.-H. Whitnall et al., Int". J. Inmunopharmacology 2000 22:1-14. U.S. patents 5,162,198, 5,206,008, 5,292,730, 5,407,684, 5,461,042, 5,461,768, 5,478,566,
5,585,371, 5,635,496, 5,641,766, 5,753,237, 5,837,269, 5,885,977 and 5,919,465, PCT publication nos. W093/20696 and W099/25333. |. Porsova-Dutoit et al., Physiological Res. 2000 49 (Suppl. 1):543-S56, R.L. Jesse et al., Ann. N. Y. Acad. Sci. 1995 774:281-290 and
U.S. patent 5,532,230, 5,811,418 and 5,846,963 discuss the capacity of 33-hydroxyandrost- . 5 5-ene-17-one, its 3-sulfate derivative and other steroids to affect platelet and neutrophil aggregation or their adhesion to endothelial cells.
[0014] U.S. patents 4,908,358 and 4,902,681 describe the capacity of compounds such as 5a-pregnan-3,20-dione, cortexolone, 17-hydroxyprogesterone and 160- methylprogesterone to inhibit the clearance of antibody-coated cells from circulation in disorders such as immune thrombocytopenic purpura or immune hemolytic anemia.
[0015] U.S. patents 5,532,230, 5,686,438, 5,753,640 and 5,811,418 and J. Bratt and
M. Heimburger, Scand. J. Rheumatol. 1999 28:308-313 describe the capacity of compounds such as 3B, 7p-dihydroxyandrost-5-ene-17-one, prednisolone, and 3p-hydroxyandrost-5-ene- 17-one to limit tissue damage in ischemic tissues by inhibiting adhesion of cells such as neutrophils to endothelial cells or to treat pulmonary hypertension.
[0016] U.S. patent 5,859,000 describes the capacity of compounds such as 38,7p- dihydroxyandrost-5-ene-17-one and 3p-hydroxyandrost-5-ene-17-one to reduce mast cell mediated allergic reactions.
[0017] U.S. patent 5,763,433 and PCT publication WO 96/35428 describe the capacity of compounds related to dehydroepiandrosterone and 16a- halodehydroepiandrosterone to modulate immune responses and to treat conditions certain "immune related conditions such as systemic lupus erythematosus.
[0018] U.S. patents 5,925,630, 5,939,545 and 5,962,443 describe the capacity of 19- nur-pregnane steroids, 3a-hydroxy-5a-pregnan-20-one and related steroids to modulate certain neurological activities such as hypothalamic function and GABA receptor activity.
[0019] Some proteins such as interleukin-6 ("IL-6"), erythropoietin ("EPO") and thrombopoietin ("TPO") have been examined for their capacity to enhance various aspects hemopoiesis, e.g., Hematology - Basic Principles and Practice, 3" edition, R. Hoffman, E.J.
Benz Jr. et al., editors, Churchill Livingstone, New York, 2000 (see, e.g., Chapter 14 at pages 154-202), O.J. Borge etal., Blood 1996 88:2859-2870, M. Cremer et al., Ann.
Hematol. 1999 78:401-407, Y. Sasaki et al., Blood 1999 94:1952-1960, U.S. patent ) 5,879,673. Recombinant IL-6 was shown in model systems to affect platelet counts in peripheral circulation, e.g., Stahl et al., Blood 1991 78:1467-1475, although significant ) toxicities are associated with its administration to humans, e.g., Andus et al., FEBS Lett. 1987 221:18, J. Gauldie et al., P.N.A.S. U.S.A. 1987 84:7251-7255, T. Geiger et al., Eur. J.
Immunol. 1988 18:717-721. The IL-6 molecule has been described in detail, e.g., publication no. WO 88/00206. Administration of proteins is typically expensive, given factors such as the complexity of producing pharmaceutical grade material.
[0020] The capacity of various compounds or agents such as deuterium oxide, lithium and butyrate to affect or to participate in biological functions of cells such as neutrophils has been described. See, e.g., M.F. Tsan and RM. Turkall, Inflammation 1982 6:387-396, M. Nakamura et al., Exp. Cell Res. 1976 102:429-431, P. Blier et al., Int. Clin.
Psychopharmacol. 1998 13:137-140, N. Turkozkan et al., Int. J. Biochem. 1993 25:1501- 1504, L.V. Deriy et al., Biochem. Biophys. Res. Commun. 2000 275:241-246,M.T.
Eighetany et al., Leuk. Res. 1997 21:801-806, E. Brandt et al., J. Leukocyte Biol. 2000 68:125-130, M. Boussac and J. Garin, Electrophoresis 2000 21:665-672, M. Niwa et al., Life
Sci. 2000 18:1525-1534, DA. Moulding etal., J. Leukocyte Biol. 1999 65:875-882 and D.
Moulding et al., Biologicals 1996 24:301-306.
[0021] There is a current need for cost-effective pharmaceutical agents or treatment methods that are more effective in treating deficiencies of blood cells or reducing their symptoms. The present invention provides therapeutic agents and treatment methods to treat hemopoiesis deficiencies and disorders such as TP and NP. The agents and methods are thus useful to reduce one or more symptoms associated with any of these conditions.
Also, the use of the invention agents and methods can be combined with one or more conventional reatments for these disorders.
[0022] Summary of invention embodiments. The invention provides for the use of a compound of formula 1 to prepare a medicament for the treatment of a blood cel! deficiency in a subject wherein formula 1 has the structure
RY RS R*
R10 Re 12 S R*
R® R10 | 1a BD Re
R® “] lo R” R
RI—A2_ 4 fe 6 {20 hz R
R' wh lo R
[0023] R R 1
[0024] wherein, each R', R?, R%, R*, R®, R® and R' independently are -H, -OH, -
ORM, -SR™ -N(R™),, -0-Si-(R"),, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSO;H, -
OPO;H, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a ] phosphonoester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid, a peptide, an ether, a thioether, an acyl group, a thioacyl group, a carbonate, a carbamate, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally } substituted heteroaryl moiety, an optionally substituted heterocycle, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonudeotide, a polymer, or,
[0025] one or more of both R?, R?, R® or R* together comprise an independenty selected spiro ring, or
[0026] one more of R', R%, R%, R*, R®, R® and R" are =0, =S, =N-OH, =CH,, or a spiro ring and the hydrogen atom or the second variable group that is bonded to the same carbon atom is absent, or,
[0027] one or more of two adjacent R'-R°® and R'° comprise an independently selected acetal, thioacetal, ketal or thioketal moiety, or
[0028] all R® and R* together comprise a structure of formula 2
R10 RS
RO R® D
R R10
R® ~ 9 R10 R
R! 2 R?
R! R10 R2
[0029] RY RY 2;
[0030] R’ is -C(R™)-, -C(R™),-C(R™),-, -C(R™)-C(R™),-C(R™)z-, -C(R™°),-O-
C(R"),-, -C(R™),-S-C(R%),-, -C(R'),-NR*R-C(R"°),-, -O-, -O-C(R")2~, -S-, -8-C(R"), -
NRPR- or -NRPR-C(R%),-;
[0031] R® and R® independentlyare -C(R").-, -C(R");-C(R")-, -O-, -0-C(R")-, -S-, -S-C(R")-, -NR"R- or NRPR-C(R™),-, or one or both of R® or R® independently are absent, leaving a 5-memberedring;
[0032] R'® independentlyis C, alkyl; -
[0033] RR independentlyis -H or a protecting group;
[0034] D is a heterocycle or a 4-, 5-, 6- or 7-membered ring that comprises saturated carbon atoms, wherein 1, 2 or 3 ring carbon atoms of the 4-, 5-, 6- or 7-membered ring are ] 25 optionally independently substituted with -O-, -S- or -NR™- or where 1, 2 or 3 hydrogen atoms of the heterocycle or where 1, 2 or 3 hydrogen atoms of the 4-, 5-, 6- or 7-membered ) ring are substituted with -OH, -OR™, -SR™?, -N(R™®),, -0-Si~(R")s, -CHO, -CHS, -CH=NH, -
CN, -SCN, -NO,, -OS0;H, -OPOsH, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid,
a peptide, an ether, a thioether, an acyl group, a thioacyl group, a carbonate, a carbamate, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heteroaryl moiety, an optionally substituted heterocycle, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer, or,
[0035] one more of the ring carbons in D are substituted with =O, =§, =N-OH, =CH,, or a spiro ring, or
[0036] two adjacent D ring carbons comprise an independently selected acetal, thioacetai, ketai or thioketal moiety, or
[0037] D comprises two 5- or 6-membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, or a metabolic precursor or a biologically active metabolite thereof. In some of these embodiments 1, 2, 3, 4 or more R' atthe 1, 4, 6, 8, 9, 12 and 14 positions are not hydrogen. in other embodiments, they are all hydrogen atoms.
[0038] The invention also provides for the use of a formula 1 compound to prepare a medicament for the treatment of a disease, condition or symptom that is caused by or associated with one or more of an autoimmune condition, an immune suppression condition, an infection, a cancer, a precancer, an inflammation condition, a neurological condition, a cardiovascular condition or a side-effect of radiation exposure or chemotherapy or a delayed adverse or unwanted effect of radiation exposure in a subject in need thereof. In some of these embodiments, the medicament is for administration to the subject or delivery to the subject's tissues beginning at least 1 day after the subject has been exposed to a dose of radiation that will cause or could potentially cause the one or more delayed adverse or unwanted effects of the radiation exposure or wherein the medicament is for administration to the subject or delivery to the subject's tissues beginning at least 1 day after the subject has been exposed to at least one subdose of a planned course of radiation exposures that will cause or could potentially cause the one or more delayed adverse effects or unwanted effects of the radiation exposure. In some of these embodiments 1, 2, 3, 4 or more R™ at the 1,4, 6, 8,9, 12 and 14 positions are not hydrogen. In other embodiments, they are all hydrogen atoms. :
[0039] Invention embodiments also provide a method to modulate an immune or : . cellular response in a subject in need thereof comprising administering to the subject, or delivering to the subject's tissues, an effective amount of a compound of formula 1
R10 5 RS
R10 R® N\ R . RS R10 HD—R3 7 7 R® p
R 2 ri R10 R2
R10 R10 1
[0040] wherein,
[0041] each R', R% R? R* R® R® and R" independently are -H, -OH, -ORR, -SR™®,
N(R™),, -0-Si-(R™)s, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OS0;H, -OPO;H, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a phosphonoester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid, a peptide, an ether, a thioether, an acyl group, a thioacyl group, a carbonate, a carbamate, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heteroaryl moiety, an optionally substituted heterocycle, an optionaly substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonudeotide, a polymer, or,
[0042] one or more of both R’, R?, R® or R* together comprise an independenty selected spiro ring, or .
[0043] one more of R', R?, R?, R*, R®, R® and R" independently are =O, =S, =N-OH, =CH,, or a spiro ring, and the hydrogen atom or the second variable group that is bonded to the same carbon atom is absent, or,
[0044] one or more of two adjacent R'-R® and R'™ comprise an independently selected acetal, thioacetal, ketal or thioketal moiety, or
[0045] all R® and R* together comprise a structure of formula 2
R10 i” r0 R° Db
R® R10 ss 7
R® Leo R
R! 2 R?
R' Y R10 R2
[0046] RY? RY 2,
[0047] R” is -C(R"),-, -C(R"%),-C(R),-, -C(R°),-C(R"*),-C(R"),~, -C(R"),-O-
C(R"),-, -G(R"),-S-C(R"),-, -C(R"),-NR™-C(R™),-, -O-, -0-C(R™),-, -S-, -S-C(R"");-, -
NRPR- or -NRPR-C(R"),-;
[0048] R® and R® independently are -C(R'),-, -C(R"),-C(R"),-, -O-, -O-C(R").~, -S-, -S-C(R").-, -NR™- or -NRPR-C(R"),~, or one or both of R® or R® independently are absent, leaving a 5-membered ring;
[0049] R™ independentlyis C.. alkyl;
[0050] RPR independentlyis -H or a protecting group;
[0051] D is a heterocycle or a 4-, 5-, 6- or 7-membered ring that comprises saturated carbon atoms, wherein 1, 2 or 3 ring carbon atoms of the 4-, 5-, 6- or 7-membered ring are optionally independently substituted with -O-, -S- or -NR™- or where 1, 2 or 3 hydrogen atoms of the heterocycle or where 1, 2 or 3 hydrogen atoms of the 4-, 5-, 6- or 7-membered ring are independenty substituted with -OH, -OR™R, -SRPR, -N(RPR),, -O-Si-(R™),, -CHO, -
CHS, -CH=NH, -CN, -SCN, -NO,, -OS0O4H, -OPO3H, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid, a peptide, an ether, a thioether, an acyl group, a thioacyl group,a carbonate, a carbamate, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heteroaryl moiety, an optionally substituted heterocycle, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer, or,
[0052] one more of the ring carbons in D are substituted with =O, =S, =N-OH, =CHs,, or a spiro ring, or
[0053] two adjacent D ring carbons comprise an independently selected acetal, thioacetal, ketal or thioketal moiety, or
[0054] D comprises two 5- or 6-membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, or a metabolic precursor or a biologically active metabolite thereof, optionally provided that if the subject is in need of enhanced hemopoiesis, the compound is not 5-androstene-3p-ol-17-one, 5-androstene-3,17p-diol, 5-androstene-38,7p,17p-triol or a derivative of any of these three compounds that can convert to these compounds by hydrolysis. Immune and cellular response modulation includes enhancing Th1 immune - responses, reducing Th2 immune responses, reducing inflammation and enhandng hemopoiesis. These compounds are useful in treating the diseases, conditions and : symptoms described herein.
[0055] Other embodiments include a method to enhance the expression of one or more cytokines or interleukins that facilitate Th1 or Tc1 immune responses in a subject or to reduce the expression of one or more cytokines or interleukins that facilitate Th2 or Tc2 immune response in a subject comprising administering to the subject an effective amount of of a formula 1 compound, whereby the subject's Th1 or Tc1 immune response is enhanced ot the subject's undesired Th2 or Tc2 immune response is reduced.
[0056] A further embodiment is a method to modulate a subject's innate immunity,
Th1 immune responses, Tc1 immune responses, Th2 immune responses, Tc2 immune responses, or inflammation comprising administering an effective amount of a formula 1 compound to a subject or delivering the formula 1 compound to the subject's tissues.
[0057] The formula 1 compounds are useful to prepare a medicament for use in the treatment of one or more of the diseases, conditions or symptoms described herein.
[0058] Other embodiments are as described elsewhere in the specification including the numbered embodiments and the claims.
[0059] Definitions. As used herein and unless otherwise stated or implied by context, terms that are used herein have the meanings that are defined here. The descriptions of embodiments and examples that are described illustrate the invention and they are not intended to limit it in any way. Unless otherwise contraindicated or implied, e.g., by including mutually exclusive elements or options, in these definitions and throughout this specification, the terms "a" and "an" mean one or more and the term "or" means and/or.
[0060] An “invention formulation”, “formulation” or the like means a composition that one can administer to a subject, e.g., human or animal, without further manipulations that change the ingredients or the ingredient proportions that are present. Formulations are suitable for human or veterinary applications and would typically have expeded characteristics for the formulation, e.g., parenteral formulations for human use would usually be sterile.
[0061] An “invention composition”, "composition" or the like means a composition, that is a formulation or that can be an intermediate one can use to make the formulations, i.e., a change(s) in an ingredient(s) or its amount(s) may be needed to make a formulation.
Compositions may also comprise other types of materials, e.g., reagents for assays or cells that are optionally contacted with a formula 1 compound or mixtures of compounds. Thus, . invention compositions include compositions where further processing may be required before it is a formulation, e.g., mixing or addition of a desired amount of an ingredient.
[0062] Phrases such as "administration of a compound of formula 1", "treatment with aformula 1 compound" or similar terms mean that the compound(s) is administered to, or delivered to, the subject or to the subject's tissues by one or more suitable methods, e.g., by an oral, topical, parenteral, buccal or sublingual route.
[0063] Expressions such as “a formula 1 compound(s)’, “a formula 1 compound” and the like mean invention compositions or formulations where one or more than one formula 1 compound is present, e.g., in a composition, or is used in the disclosed method, typically 1, 2, 3 or 4, usually 1. Any reference to a "formula 1 compound”, "one or more compounds of formula 1" or the like means that the formula 1 compound can have the formula 2 structure or any other structure disclosed herein that is within the definition of formula 1 compounds.
[0064] Reference to subject matter "as disclosed herein” such as a "therapeutic treatment or agent as disclosed herein”, a "dosing protocol as disclosed herein” or a "clinical condition or symptom as disclosed herein" or the like means a treatment, agent, protocol, condition, symptom or the like that is described herein or in any reference that is cited herein.
[0065] An "excipient, "carrier", "pharmaceutically acceptable carrier” or similar terms mean one or more component(s) or ingredient(s) that is acceptable in the sense of being compatible with the other ingredients of invention compositions or formulations and not overly deleterious to the patient, animal, tissues or cells to which the formulation is to be administered.
[0066] As used here, “excipients” include liquids, such as benzyl benzoate, cottonseed oil, N,N-dimethylacetamide, a C,.1» alcohol (e.g., ethanol), glycerol, peanut oil, a polyethylene glycol (“PEG”), vitamin E, poppyseed oil, propylene glycol, safflower oil, sesame oil, soybean oil and vegetable oil. Any solid excipient may be a fine powder or granulated. Excipients, as used herein may optionally exclude one or more excipient, e.g., chloroform, dioxane, vegetable oil, DMSO, other excipients or any combination of these.
Excipients include one or more components typically used in the pharmaceutical formulation arts, e.g., one, two or more of fillers, binders, disintegrants, dispersants, preservatives, glidants and lubricants. Exemplary excipients include povidone, crospovidone, corn starch, carboxymethyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, gum arabic, polysorbate 80, butylparaben, propylparaben, methylparaben, BHA, EDTA, sodium lauryl sulfate, sodium chloride, potassium chloride, titanium dioxide, magnesium stearate, castor oil, olive oil, vegetable oil, buffering agents such as sodium hydroxide, monobasic . sodium phosphate, dibasic sodium phosphate, potassium hydroxide, monobasic potassium phosphate, dibasic potassium phosphate, tribasic potassium phosphate, potassium carbonate, potassium bicarbonate, ammonium hydroxide, ammouium chloride, saccharides such as mannitol, glucose, fructose, sucrose or lactose any of which may be compressible or any of which may be spray dried.
[0067] A “subject” means a human or animal. Usually the animal is a mammal or vertebrate such as a primate, rodent, lagomorph, domestic animal or game animal. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g.,
Rhesus or Pan. Rodents and lagomorphs include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, sheep, deer, bison, buffalo, mink, felines, e.g., domestic cat, canines, e.g., dog, wolf and fox, avian species, e.g., chicken, turkey, emu and ostrich, and fish, e.g., trout, catfish and salmon. Subject includes any subset of the foregoing, e.g., all of the above, but excluding one or more groups or species such as humans, primates or rodents. Other subsets of subjects include subjects of a given species or group of species of varying ages, e.g., young humans, e.g., about 1 week of age to about 9 years of age, adolescent humans, e.g., about 10-19 years of age, adult humans, e.g., about 20-100 years of age, and mature adult or elderly humans, e.g., at least about 55 years of age, at least about 60 years of age, at least about 65 years of age ora range of ages such as about 60-100 years of age. Thus, as used herein, prevention or treatment of a disease, condition or symptom may include or exclude any subset of subjects that are grouped by age.
[0068] The terms "effective amount”, "effective dose" or the like mean an amount of a formula 1 compound that is sufficient to elicit a desired response, e.g., restoration of normal immune responsiveness in an immunodeficient subject to which it is administered or to detectable modulation or amelioration of an immune or cellular parameter or a clinical condition or symptom. An effective amount may be a a single dose or two or more subdoses of a forlula 1 compound administered in one day, or it may be administered as multiple doses over a period of time, e.g., over 2 days to about 1 year.
[0069] References such as "a disease”, "a disorder”, "a condition”, "a symptom’ or "a complication” or the like mean that one or more disease, disorder, condition, symptom or complication may be treated.
[0070] Terms such as "use", "treat", "treatment", "address" or the like in the context of using the formula 1 compounds in the treatment methods or other methods disclosed herein mean that a formula 1 compound is administered to a subject, delivered to the subject's tissues or contacted with tissues, cells or cell free systems, e.g., as described herein or a reference cited herein. Typically such use or treatment results in detectable . improvement in or amelioration of the condition or symptom being treated. Such amelioration may be transient, e.g., lasting for at least a few, e.g., about 1 to 24, hours or days, e.g., about 1-,7 days, or amelioration may be prolonged, e.g., lasting about 8 to about 60 days or more, or it may be permanent. A treatment may slow the progression or severity of a disease or symptom. A use or treatment may result in detectable modulation in a relevant immune parameter such as modulation of the level or activity of a target effector or suppressor immune cell population, interleukin, cytokine, chemokine, immunoglobulin or modulation of the level or activity of a relevant transcription factor, enzyme or cell biological activity. A treatment with the compounds may be used to prevent the onset of a disease, symptom or complication or to ameliorate a preexisting disease, condition, symptom or complication, or to facilitate elimination of a disease, condition, symptom or complication.
[0071] "Ameliorate”, "amelioration", "improvement" or the like means a detectable improvement or a detectable change consistent with improvement occurs in a subject or in at least a minority of subjects, e.g., in atleast about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 100% or in a range aboutbetween any two of these values. Such improvement or change may be observed in treated subjects as compared to subjects not treated with a formula 1 compound, where the untreated subjects have, or are subject to developing, the same or similar disease, condition, symptom or the like. Amelioration of a disease, condition, symptom or assay parameter may be determined subjectively or objectively, e.g., self assessment by a subject(s), by a clinician's assessment or by conducting an appropriate assay or measurement, including, €.g., a quality of life assessment, a slowed progression of a disease(s) or condition(s), a reduced severity of a disease(s) or condition(s), or a suitable assay(s) for the level or activity(ies) of a biomolecule(s), cell(s) or by detection of cell migration within a subject. Amelioration may be transient, prolonged or permanent or it may be variable atrelevanttimes during or after a formula 1 compound is administered to a subject or is used in an assay or other method described herein or a cited reference, e.g., within about 1 hour of the administration or use of a formula 1 compound to about 3, 6, 9 months or more after a subject(s) has received a formula 1 compound.
[0072] The "modulation" of, e.g., a symptom, level or biological activity of a molecule, replication of a pathogen, cellular response, cellular activity or the like, means that the cell, level or activity, or the like is detectably increased or decreased. Such increase or decrease may be observed in treated subjects as compared to subjects not treated with a formula 1 compound, where the untreated subjects have, or are subject to developing, the same or similar disease, condition, symptom or the like. Such increases or decreases may be at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, . 95%, 98%, 100%, 150%, 200%, 250%, 300%, 400%, 500% or more or about within any range about between any two of these values. Modulation may be determined subjectively or : objectively, e.g., by the subject's self assessment, by a clinician's assessment or by conducting an appropriate assay or measurement, including, e.g., quality of life assessments or suitable assays for the level or activity of molecules, cells or cell migration within a
Claims (1)
- CLAIMS What is claimed is:1. Use of a compound to prepare a medicament for the treatment of a blood cell deficiency in a subject wherein the compound has the structure R10 5 RE R10 i. RIO R812 "\ RY \ RO R® D J R R10 14 y x J R R10 il “1 Yo go] fo RT R R® ” RY | R™ " RI—AR_ 4 Ae 6 R' AR R? R R10 R10 or R10 R10 wherein, each R', R? R? R® R°® and R" independently are -H, -OH, -ORR, - SR™, -N(R™),, =0, =8, =NOH, =CH,, -0-Si-(R"?)s, -CHO, -CHS, -CH=NH, -CN, -SCN, - NO,, -OSO;H, -OPO;H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a spiro ring or a polymer, or one or more of E two adjacent R'-R® and R*® comprise an independently selected acetal, thioacetal, ketal or thioketal; one R*is -OH, -OR™R, -SH, -SR™®, -0-Si-(R")s, -N(RR),, thioester, BN _ phosphoester, phosphothioester, sulfite ester, sulfate ester, thioether, carbamate, carbonate, polymer, an ether optionally selected from -OCHj3 and -OC,H;s or an ester optionally selected from -O-C(O)-CH; and -O-C(O)-C,Hs and the other R* is -H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, acyl, thioacyl, heterocycle, -SCN or -CN; Ris -C(R")-, -C(R"*)-C(R™)-, -C(R™)2-C(R*)-C(R™)z-, -C(R")2-O-C(R"),-, - . C(R'),-S-C(R"),-, -C(R"),-NRPR-C(R),-, -O-, -O-C(R'®),-, -S-, -S-C(R"°),-, -NR™®- or - LY NRPR-C(R"%),-; . -369- AMENDED SHEET 25.10.2004R® and R® independently are -C(R*)-, -C(R'%),-C(R")-, -O-, -O-C(R")-, -S-, -S- C(R'%),-, -NR™R- or -NR"R-C(R").-, or one or both of R® or R® independently are absent, leaving a 5-membered ring,R" independently is C1. alkyl;R™ independently are -H or a protecting group;D is a heterocycle or a 4-, 5-, 6- or 7-membered ring that comprises saturated carbon atoms, wherein 1, 2 or 3 ring carbon atoms of the 4-, 5-, 6- or 7-membered ring are optionally independently substituted with -O-, -S- or -NR"®- or where 1, 2 or 3 hydrogen atoms of the heterocycle or where 1, 2 or 3 hydrogen atoms of the 4-, 5-, 6- or 7-membered ring are substituted with -OH, -OR™, -SR™, -N(R"®),, -O-Si-(R")s, -CHO, - CHS, -CH=NH, -CN, -SCN, -NO,, -OSO;H, -OPO;H, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid, a peptide, an ether, a thioether, acyl, thioacyl, carbonate, carbamate, a thioacetal, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer, or, one more of the ring carbons in D are substituted with =O, =S, =N-OH, =CH,, or a spiro ring, or two adjacent D ring carbons comprise an independently selected acetal, thioacetal, ketal or thioketal moiety, or D comprises two 5- or 6- membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, or a metabolic precursor or a biologically active metabolite thereof, provided that 1, 2 or 3 R* atthe 1, 4, 6, 8, 9, 12 and 14 positions are not hydrogen and(a) one R'is -OH, -OR™®, -SR™R, -N(R™),, -O-8i-(R")s, -SCN, -NO,, -OSO;H, - OPO;H, -NH-C(0)-C;. optionally substituted alkyl, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer, and the other R' is -CHO, -CHS, -CH=NH, -CN, -C(O)-NH-C,., optionally substituted alkyl, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle; or(b) one R?is -OH, -OR™®, -SR™®, -N(R™),, -O-Si-(R"%)s, -SCN, -NO,, -OSO;H, - OPO;H, -NH-C(0)-C,.5 optionally substituted alkyl, ester, thioester, thionoester,-370- AMENDED SHEET 25.10.2004 :phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer, and the other R%is -CHO, -CHS, -CH=NH, -CN, -C(0)-NH-C1.50 optionally substituted alkyl, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle; or(c) one R® is OH, -OR™®, -SR™, -N(R™),, -O-Si-(R")3, -SCN, -NO,, -OSO;H, - OPO;H, -NH-C(0O)-C +.» optionally substituted alkyl, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer, and the other Ris -H, -CHO, -CHS, -CH=NH, -CN, -C(0O)-NH-C,.,, optionally substituted alkyl, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle; or(d) a double bond is present at the 5-6 position and optionally at the 1-2 or 16-17 positions and R® is -CHR’- where the R™ is -OH, -OR™R, -SRPR, -N(RPR),, -O-Si-(R"?),, - SCN, -NO,, -OS0O;H, -OPO;H, -NH-C(0)-C,.» optionally substituted alkyl, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer or C,.5 optionally substituted alkyl; or(e) a double bond is present at the 5-6 position and optionally at the 1-2 or 16-17 positions and R’ is -O-, -S-, -NH-, -CHR™- where the R'is -OH, -SH, =O, =S, -CN, - SCN, -NO,, -F, -Cl, -Br, -l, ether, thioether, ester, thioester or C,» optionally substituted alkyl; or(f) a double bond is present at the 5-6 position and optionally at the 1-2 or 16-17 positions and R® is -O-, -S-, -NH-, -CHR'’- where the R'® is -SCN, -NO,, -F or C1. optionally substituted alkyl; or(g) a double bond is present at the 5-6 position and optionally at the 1-2 or 16-17 positions and R® is -O-, -S-, -NH-, -CHR"- where the R'® is -OH, -SH, =O, =S, -CN, - SCN, -NO,, -F, -Cl, -Br, I, ether, thioether, ester, thioester or C5, optionally substituted alkyl.-371- AMENDED SHEET 25.10.20042. Use according to claim 1 wherein one or two R atthe 1, 4,6, 8,9, 12 and 14 positions independently are -OH, -OR™, =O, -SH, -SR™, -N(R™),, =S, -F, -C|, - Br, -1, C1-C8 optionally substituted alkyl, thioester, thioether, optionally substituted monosaccharide, optionally substituted oligosaccharide, amino acid, amide, carbamate, carbamate, polymer, an ether optionally selected from -OCH; and -OC.Hs, or an ester optionally selected from -O-C(O)-CH; and -O-C(O)-C,Hs.3. Use according to claim 1 or 2 wherein (a) R* in the B-configuration is -OH, -OR™, -SH, -SR™, -O-Si-(R")s, -N(R™), thioester, phosphoester, phosphothioester, sulfite ester, sulfate ester, thioether, carbamate, amide, carbonate, polymer, an ether optionally selected from -OCH, and - OC,Hs or an ester optionally selected from -O-C(O)-CHs and -O-C(0)-C,Hs and R* in the a-configuration is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, acyl, thioacyl, -SCN or -CN; or (b) R* in the a-configuration is -OH, -ORR, -SH, -SR™, -O-Si-(R");, -N(R™),, thioester, phosphoester, phosphothioester, sulfite ester, sulfate ester, thioether, carbamate, amide, carbonate, polymer, an ether optionally selected from -OCH,; and - OCH; or an ester optionally selected from -O-C(Q)-CHj; and -O-C(0)-C;Hs and R* in the B-configuration is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, acyl, thioacyl, -SCN or -CN. 4, Use according to claim 1, 2 or 3 wherein (a) the one or two R'® at the 4, 6 and 9 positions are independently selected from -F, -Cl and -OH; or : (b) one of R', R%, R® and R* is -O-C(0)-0-C,.; optionally substituted alkyl, -O- C(O)-N-C,.2 optionally substituted alkyl, -N-C(O)-O-C;.o optionally substituted alkyl or - S-C(0)-0-C1.4 optionally substituted alkyl.5. Use according to claim 1, 2, 3 or 4 wherein (a) one R*is -OH, -SH, - N(RFF),, ester, ether, carbonate, amino acid or carbamate and the other R* is -CHs, - C,Hs, -CCH, -CCCH,, -CH=CH, or Cs alkyl or (b) R™ at the 9-position is -F or -Cl. -372- AMENDED SHEET 25.10.20046. Use according to claim 1 wherein the subject has thrombocytopenia or neutropenia or the subject is susceptible to developing thrombocytopenia or neutropenia.7. Use according to claim 1 wherein the subject's circulating platelets, red cells, myelomonocytic cells, or their precursor cells, in circulation or in tissue is detectably increased.8. Use according to claim 7 wherein the subject's circulating neutrophils or platelets are detectably increased.9. Use according to claim 7 wherein the subject's circulating red cells are detectably increased.10. Use according to claim 7 wherein the subject has a cancer or precancer or wherein the blood cell deficiency is associated with radiation exposure or an immunosuppressive chemotherapy wherein the immunosuppressive chemotherapy optionally is a cancer chemotherapy or a glucocorticoid therapy.11. Use according to claim 7 wherein the subject is has renal failure.12. Use according to any preceding claim wherein the subject is a human or a primate.13. A compound of formula V Rs Riz SA: Rg . R AN Ry2 J RY ALC RAR, . Nl PZ NT X g -373- AMENDED SHEET 25.10.2004 or a pharmaceutically acceptable salt, ester, amide, prodrug or analog wherein, the dotted lines are single or double bonds, X is oxygen, sulfur, =CH, or =NOH, one of Ry and R; is -H and the other is a glucuronide having the formula Ry 0) TL Re” Ripa wherein R; is an alkyl ester wherein the alkyl moiety is optionally substituted, and Rs, Ry and Roa independently are -ORy,, where Ry, is H, a protecting group or optionally substituted alkyl; Rs and Rs independently or together are -H, -OH, -OR™, =0, -SH, =S, -SR™, ester, thioester, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or optionally substituted alkyl; R™ is -C(R")-, -C(R")-C(R")-, -C(R™)-C(R™),-C(R*)z-, -C(R"*)-O-C(R")-, - C(R"%),-S-C(R"),-, -C(R"),-NR™-C(R"),-, -O-, -O-C(R").-, -S-, -S-C(R®),-, -NR"*- or - NRPR-C(R"),~; R® and R* independently are -C(R'%),-, -C(R'%),-C(R""),-, -O-, -O-C(R"),-, -S-, - S-C(R™),-, -NR™- or -NR™-C(R),-, or one or both of R* or R* independently are absent, leaving a 5-membered ring; each R'® independently is -H, -OH, -OR™:, -SR™, -N(R™),, -0-Si-(R"®)5, -CHO, - CHS, -CH=NH, -CN, -SCN, -NO,, -OSO3H, -OPOsH, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer;R.. and Ry; independently are -H, -OH, -OR™ or optionally substituted alkyl; and R™ independently are -H or a protecting group, wherein the compound is optionally substituted at one or two of the 1-, 4-, 6-, 8-, 9-, 12- and 14-positions with an independently selected moiety selected from -OH, - ORR, -SR™, -N(R"®),, -O-Si-(R™)s, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSO;H, - OPO3H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, -374- AMENDED SHEET 25.10.2004 phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, nucleoside, nucleotide, oligonucleotide and polymer.14. The compound of claim 13, wherein Ry, is an ester or wherein a double bond is present at the 4-5 position or at the 16-17 position.15. The compound of claim 13 or 14, wherein (a) Ry, is -H and Ry; is -CH; or -C;Hs, (b) one or two of the 1-, 4-, 6-, 8-, 12- and 14-positions is substituted, (c) the 9- position is substituted, optionally wherein the substituent at the 9-position is -F, -Cl, -OH or C4.50 optionally substituted alkyl or (d) a double bond is present at the 5-6 position or at the 1-2 and 5-6 positions.16. A formulation comprising a compound of claim 13, 14 or 15 and one or more excipients.17. A compound of formula VII Ryz 3s 8A WRg R \ Riz y ROAT RA R;,0 7 Pa tl Ry VII or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein the dotted lines are optional double bonds; one of R; and R, is -H and the other is a glucuronide group having the formula -375- AMENDED SHEET 25.10.2004. R; 0 ra Ry Rioa :R; is an alkyl ester wherein the alkyl moiety is optionally substituted;Rs, Rg and R404 independently are -OR44, where Ry, is -H, a protecting group or optionally substituted alkyl;Rs and Rs independently or together are -H, -OH, -OR™, =0, -SH, -SR™, =S, ester, thioester, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or optionally substituted alkyl;Ry, is -H or a protecting group;R™ is -C(R")z-, -C(R")-C(R™)-, -C(R™)-C(R™),-C(R")2-, -C(R')-O-C(R"™).-, - C(R"),-S-C(R"),-, -C(R"),-NR™-C(R"),-, -O-, -O-C(R®),-, -S-~, -S-C(R"’),-, -NR™- or - NRPR-C(R'),-;R% and R*! independently are -C(R'®),-, -C(R"*),-C(R®).-, -O-, -O-C(R")-, -S-, - S-C(R"),-, -NR"?- or -NRPR-C(R"),-, or one or both of R* or R* independently are absent, leaving a 5-membered ring;each R' independently is -H, -OH, -ORR, -SRPR, -NH,, -NHRR, -N(R™®),, -O-Si- (R™)s, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSO;H, -OPO:H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer;R,2 and Ry; independently are -H, -OH, -OR™ or optionally substituted alkyl; andRR independently are -H or a protecting group,wherein the compound is optionally substituted at one or two of the 1-, 4-, 6-, 8-, 9-, 12- and 14-positions with an independently selected moiety selected from -OH, - OR™, -SR™, -N(R™),, -0-Si-(R")s, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSO;H, - OPO3H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether,-376- AMENDED SHEET 25.10.2004 acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, nucleoside, nucleotide, ~ oligonucleotide and polymer.18. The compound of Claim 17, wherein one of R; and R, is a hydrogen atom and the other one of R, and R; is the glucuronide.19. The compound of Claim 17 or 18, wherein one of Rs and Rg is a -H or optionally substituted alkyl and the other one of Rs and Rs is an ester optionally selected from acetoxy and propionoxy.20. The compound of Claim 17, 18 or 19, wherein Ry is -H or -CHs and Ry; is -CHj; or -C,Hs.21. The compound of claim 17 wherein (i) the compound is methyl-2,3,4-tri-O-acetyl-1-O-(3p,17p-diacetoxyandrost-5- ene-7p-yl)-B-D-gluco-pyranosiduronate, methyl 1-O-(3p,17p-diacetoxyandrost-5-ene-7f3- yl)-B-D-gluco-pyranosiduronate or methyl-2,3,4-tri-O-acetyl-1 -O-(3p-acetoxy-1 7- oxoandrost-5-ene-7a-yl)-p-D-glucopyranosiduronate, or a pharmaceutically acceptable salt, ester, ether, amide, or prodrug thereof, or (ii) one or two of the 1-, 4-, 6-, 8-, 12- and 14-positions is substituted, or (iii) the 9-position is substituted, optionally wherein the substituent at the 9- position is -F, -Cl, -OH or C,.o, optionally substituted alkyl, or (iv) a double bond is present at the 5-6 position or at the 1-2 and 5-6 positions, or (v) Riz is -H and Ry3 is -CH; or -C,Hs.23. A compound of formula IX -377- AMENDED SHEET 25.10.2004Riz 3s REA Na Riz p : ROA? z R7A Rr ~ 2 tl R; FY %s x or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, :wherein one of R, and R; is -H and the other is -O-C(0)-OR,4, where Ry, is -H, a protecting group or optionally substituted alkyl;one of Rs, and Rs is -H or optionally substituted alkyl and the other is -OH, -OR™%, =Q, -SH, =S, -SRR, ester, thioester, ether, thioether, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide;R,, and R; independently or together are -H, -OH, -OR™, =0, -SH, =8S, -SR™}, ester, thioester, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or optionally substituted alkyl;R™ is -C(R")-, -C(R"),-C(R"),-, -C(R"*),-C(R"%)-C(R"°),-, -C(R"%),-O-C(R"),-, - C(R"%),-S-C(R"),-, -C(R"*),-NR"R-C(R?),-, -O-, -O-C(R"?),-, -S-, -S-C(R"%),-, -NR™R- or - N RPR-C(R").~;R® and R*! independently are -C(R'®),-, -C(R"),-C(R"’),-, -O-, -O-C(R"),-, -S-, - S-C(R™),-, -NR™- or -NRPR-C(R"°),-, or one or both of R® or R® independently are absent, leaving a 5-membered ring;each R" independently is -H, -OH, -OR™®, -SRPR, -NH,, -NHR®, -N(R™?),, -O-Si- (R™)s, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSO;H, -OPO;H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, - optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer;Rs, and R,; independently are -H, -OH, -OR™R, -SH, -SRR or optionally substituted alkyl;R™ independently are -H or a protecting group,-378- AMENDED SHEET 25.10.2004 wherein the compound is (i) substituted at one or two of the 1-, 4-, 6-, 8-, 9-, 12- and 14-positions with an independently selected moiety selected from -OH, -ORR, - SR™, -N(R™R),, -0-Si-(R"™)s, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSO3H, - OPOsH, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, nucleoside, nucleotide, oligonucleotide and polymer, (ii) a double bond is present at the 16-17 position or (iii) the compound is 3B-carbomethoxyandrost-5-ene-7,17-dione, 3B-carboallyloxyandrost-5- ene-7,17-dione, 3p-carboethoxyandrost-5-ene-7,17-dione, 3B-carboisobutoxyandrost-5- ene-7,17-dione, 3B,17B-dicaromethoxyandrost-5-ene-7-one, 3f3-carbooctyloxyandrost-5- ene-7,17-dione, 3B-carbo(9-fluorenyl)methoxyandrost-5-ene-7,17-dione, 3B- carbomethoxyandrost-5-ene-7,17-diol, 3-carboethoxyandrost-5-ene-78,178-diol, 3- carbooctyloxyandrost-5-ene-7,17B-diol or a pharmaceutically acceptable salt, ester, ether, amide, or prodrug of any of these compounds.24. The compound of claim 23, wherein Ry, is an ester.25. The compound of claim 23 or 24, wherein one of R; and R; is a hydrogen atom and the other one of Ry and R; is -O-C(O)-OR 4.26. The compound of claim 24 or 25, wherein Ry, is selected from the group consisting of methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, t-butyl, pentyl, hexyl, n- octyl, n-dodecyl, 1-ethoxyethyl, 9-fluorenylmethyl, -CH,-C(O)CH; and -C(O)CHs.27. The compound of claim 23 or 24, wherein Rs and Rs independently or together are -H, -OH, =O, -O-C(0)-OCHs, -O-C(0)-OC;Hs, -0-C(0)-OC3H;, -O-C(O)- OC Hs, -O-C(0)-OCH,C,H3, -O-C(O)-OCH,C3H; or -O-C(0)-O-(CH,),-0-C.Hs.28. The compound of claim 23 or 24, wherein R;; is -H and R,; is -CHj3 or - C,Hs. -379- : AMENDED SHEET 25.10.200429. The compound of claim 23 selected from the group consisting of 3p- carbomethoxyandrost-5-ene-7,17-dione, 3p-carboallyloxyandrost-5-ene-7,17-dione, 3f- carboethoxyandrost-5-ene-7,17-dione, 3B-carboisobutoxyandrost-5-ene-7,17-dione, 3B,17B-dicaromethoxyandrost-5-ene-7-one, 38-carbooctyloxyandrost-5-ene-7,17-dione, 3B-carbo(9-fluorenyl)methoxyandrost-5-ene-7,17-dione, 3p-carbomethoxyandrost-5-ene- 7,17B-diol, 3B-carboethoxyandrost-5-ene-78,17B-diol, and 3B-carbooctyloxyandrost-5- ene-7B,17B-diol, or a pharmaceutically acceptable salt, ester, ether, amide, or prodrug thereof.30. A formulation comprising a compound of claim 17, 18, 19, 23, 24, 25, 26, 27, 28 or 29 and one or more excipients.31. Use of a compound according to claim 1, 2, 3, 4, 17, 23 or 29 to prepare a medicament for the treatment of a disease, condition or symptom that is caused by or associated with one or more of an autoimmune condition, an immune suppression condition, an infection, a cancer, a precancer, an inflammation condition, a neurological : condition, a cardiovascular condition, a pulmonary condition or a side-effect of radiation exposure or chemotherapy or a delayed adverse or unwanted effect of radiation exposure in a subject in need thereof, wherein for treatment of the delayed adverse effect of radiation exposure, the medicament is for administration to the subject or delivery to the subject's tissues beginning at least 1 day after the subject has been exposed to a dose of radiation that will cause or could potentially cause the one or more delayed adverse or unwanted effects of the radiation exposure or wherein the medicament is for administration to the subject or delivery to the subject's tissues beginning at least 1 day after the subject has been exposed to at least one subdose of a planned course of radiation exposures that will cause or could potentially cause the one or more delayed adverse effects or unwanted effects of the radiation exposure.32. Use according to claim 31 wherein the subject has, or is subject to developing, a delayed adverse or unwanted effect of radiation exposure, and wherein the subject has received or will receive a total radiation dose of at least about 0.5 Gy to about 300 Gy, at least about Gy 1 to about 200 Gy or at least about Gy 2 to about 150 -380- : AMENDED SHEET 25.10.2004Gy, wherein the subject received the radiation dose in a single dose or in two or more divided doses.33. Use according to claim 32 wherein the symptom or condition associated with one or more delayed adverse effect of radiation is one or more of encephalopathy, myelopathy, nausea, vomiting, diarrhea, acute inflammation, chronic inflammation, edema, pain, headache, depression, fever, malaise, weakness, hair loss, skin atrophy, skin ulceration, skin lesion, keratosis, telangiectasia, infection, hypoplasia, atrophy, fibrosis, fibrosing alveolitis, pneumonitis, bone marrow hypoplasia or hemorrhage.34. Use according to claim 33 wherein the symptom or condition associated with one or more delayed adverse or unwanted effect of the radiation exposure is caused by or associated with radiation damage to one or more of bone marrow cells, bowel epithelium, bone marrow, testicles, ovaries, brain nerves or tissue, peripheral nerves, spinal cord nerves or tissue or skin epithelium.35. Use according to claim 31 wherein the subject has, or is subject to developing, an autoimmune, allergy or inflammatory condition, optionally selected from multiple sclerosis, systemic lupus erythematosus, chronic asthma, acute asthma, Crohn's disease, ulcerative colitis, osteoarthritis, rheumatoid arthritis, psoriatic arthritis or psoriasis.36. Use according to claim 31 wherein the subject has, or is subject to ~ developing, an infection optionally selected from a DNA virus infection, an RNA virus infection, a fungal infection, a bacterial infection or a parasite infection.37. Use according to claim 31 wherein the subject has, or is subject to developing, a neurological condition optionally selected from Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, insomnia, migraine headache, epilepsy, schizophrenia, depression or memory impairment.38. Use according to claim 31 wherein the subject has, or is subject to developing, a cardiovascular or metabolic condition optionally selected from congestive cardiomyopathy, hypertrophic cardiomyopathy, myocardial fibrosis, an aneurysm, an -381- AMENDED SHEET 25.10.2004 arterial occlusive disease, atherosclerosis, arteriosclerosis, thrombosis, cerebral infarction, obesity, type | diabetes, type | diabetes, hypertension, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia or impaired fatty acid metabolism.39. Use according to claim 31 wherein the subject has, or is subject to developing, a cancer, a precancer or a hyperproliferation condition optionally selected from breast cancer, lung cancer, colon cancer, prostate cancer, myelodysplastic syndrome, actinic keratosis, leiomyoma, fibromyoma, benign or precancerous intestinal or bowel polyps or benign prostatic hyperplasia.40. Use according to claim 31 wherein the subject has, or is subject to developing, a pulmonary disorder optionally selected from chronic bronchitis, lung fibrosis, right ventricular hypertrophy, pulmonary hypertension, emphysema, asthma or a chronic obstructive pulmonary disease.44. Use of a compound of claim 17 or 23 for the preparation of a medicament. 45, Use of a compound for the preparation of a medicament, wherein the compound has the structure RY 0s Re | RY os 4 RT R812 \ R , RT R® D R R [4 J R R R10 : <a R’ R ze’ 7 R**1 Yo RO | R© R® R10 R R! 3 4_ A. 6 R’ LZ R? 1 J R? 1 YY 2 / R10 R2 R R10 R R R10 R10 or R10 R10 wherein, R' independently or together are -H, -OH, -OR™, -SR™, -N(R™),, =0, =S, =N- OH, =CH,, -O-Si-(R")s, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSO3H, -OPO;H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, -382- AMENDED SHEET 25.10.2004 optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer or a spiro ring;each R%, R?, R®, R® and R' independently or together are -H, -OH, -OR™, -SRP}, -N(R™),, =0, =8, =N-OH, =CH,, -0-Si-(R");, -CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, - OSO;H, -OPO;H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer, a spiro ring or,one or more of two adjacent R'-R® and R'® comprise an independently selected acetal, thioacetal, ketal or thioketal moiety, orR* independently or together are -OH, -OR™R, -SR™, -N(R™),, =S, =N-OH, =CH,, -0-Si-(R™);, “CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSOH, -OPO;H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer or a spiro ring;Ris -C(R"%),-, -C(R'%),-C(R®).-, ~C(R")-C(R'®),-C(R"),-, -C(R"),-O-C(R"®),-, - C(R"),-S-C(R"),-, -C(R"),-NR™-C(R"),-, -O-, -O-C(R"),-, -S-, -S-C(R'®),-, -NR™R- or - NR™R-C(R"),-;R® and R® independently are -C(R'),-, -C(R'%),-C(R"°),-, -O-, -O-C(R"),-, -S-, -S- C(R"),-, -NR™R- or -NRPR-C(R"),-, or one or both of R® or R® independently are absent, leaving a 5-membered ring;R" independently is C,.; alkyl;R™ independently are -H or a protecting group;D is a heterocycle or a 4-, 5-, 6- or 7-membered ring that comprises saturated carbon atoms, wherein 1, 2 or 3 ring carbon atoms of the 4-, 5-, 6- or 7-membered ring-383- AMENDED SHEET 25.10.2004 are optionally independently substituted with -O-, -S- or -NR"R- or where 1, 2 or 3 hydrogen atoms of the heterocycle or where 1, 2 or 3 hydrogen atoms of the 4-, 5-, 6- or 7-membered ring are substituted with -OH, -OR™, -SRPR, -N(R™®),, -O-Si-(R"),, -CHO, - CHS, -CH=NH, -CN, -SCN, -NO,, -OSO3H, -OPO3H, =0, =S, =N-OH, =CH,, a spiro ring, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid, a peptide, an ether, a thioether, acyl, thioacyl, carbonate, carbamate, a thioacetal, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer, or,two adjacent D ring carbons comprise an independently selected acetal, thioacetal, ketal or thioketal moiety, or D comprises two 5- or 6-membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, or a metabolic precursor or a biologically active metabolite thereof, provided that 1,2 or 3 RY atthe 1, 4, 6, 8, 9, 12 and 14 positions are not hydrogen and one or more of the following structural features are present:(a) one R'is -OH, -ORR, -SR™, -N(R™),, -O-Si-(R"®)3, -SCN, -NO,, -OSO;H, - OPOzH, -NH-C(0)-C,.5, optionally substituted alkyl, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer, and the other R' is-CHO, -CHS, -CH=NH, -CN, -C(0)-NH-C;._, optionally substituted alkyl, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle,- (b)R" are -H and one each of R?, R® and R* independently are -OH, -OR™, - SR™, -N(R™),, -O-Si-(R™)s, -NO,, -OSO;H, -OPO;H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacyl group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer,-384- AMENDED SHEET 25.10.2004(c) one R? is -OH, -OR™, -SR™, -N(R™®),, -O-Si-(R*)s, -SCN, -NO,, -OSO;H, - OPO;H, -NH-C(0)-C,.5 optionally substituted alkyl, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer, and the other R?is -CHO, -CHS, -CH=NH, -CN, -C(O)-NH-C,., optionally substituted alkyl, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, (d) one R¥is -OH, -OR"®, -SR™®, -N(R™®),, -O-Si-(R™)s, -SCN, -NO,, -OSO;H, - OPO;H, -NH-C(0)-C,.5, optionally substituted alkyl, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer, and the other R® is -CHO, -CHS, -CH=NH, -CN, -C(O)-NH-C,.,, optionally substituted alkyl, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, or ‘ (e) a double bond is present at the 16-17 position.46. A formulation comprising one or more excipients and a compound of claim 45, wherein the formulation optionally is a sterile parenteral liquid formulation, an oral formulation, a buccal formulation, a sublingual formulation or an aerosol formulation.47. Use of a compound for the preparation of a medicament, wherein the compound has the structure R10 5 RY R10 i. RO RE 12 \ R* ; RO R8 D J R R10 14 b x J R R10 ; RO%1 lio R" R RO = Lio R R—A_4 Re. 6 R’ 2 R? r lio Y L2 RP 1 YY S10 2 R' R10 R R10 R or R R10 R R10 R -385- AMENDED SHEET 25.10.2004 wherein,each R', R% R?, R* R® R® and R" independently or together are -H, -OH, -OR™, -SRPR, -N(R™),, -N3, =0, =8, =N-OH, =CH,, -O-Si-(R");, -CHO, -CHS, -CH=NH, -CN, - SCN, -NO,, -OSO;H, -OPO3H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amide, amino acid, peptide, ether, thioether, acyl group, thioacy! group, carbonate, carbamate, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer, a spiro ring or, one or more of two adjacent R'-R® and R'® comprise an independently selected acetal, thioacetal, ketal or thioketal moiety, orRis -C(R")z-, -C(R")2-C(R"),-, -C(R™),-C(R")2-C(R""), -C(R"),-0-C(R")-, - C(R"),-S-C(R"%),-, -C(R"*)-NR"?-C(R")-, -O-, -O-C(R'%),-, -S-, -S-C(R"),-, -NR™- or - NRPR-C(R),-;R® and R? independently are -C(R"),-, -C(R),-C(R™),-, -O-, -O-C(R"%),-, -S-, -S- C(R").-, -NRPR- or -NR"R-C(R"°),-, or one or both of R® or R® independently are absent, leaving a 5-membered ring;R" independently is C1. alkyl;R™ independently is -H or a protecting group;D is a heterocycle or a 4-, 5-, 6- or 7-membered ring that comprises saturated carbon atoms, wherein 1, 2 or 3 ring carbon atoms of the 4-, 5-, 6- or 7-membered ring are optionally independently substituted with -O-, -S- or -NR™®- or where 1, 2 or 3 hydrogen atoms of the heterocycle or where 1, 2 or 3 hydrogen atoms of the 4-, 5-, 6- or 7-membered ring are substituted with -OH, -OR™, -SR™, -N(R™),, -N3, -O-Si-(R")s, - CHO, -CHS, -CH=NH, -CN, -SCN, -NO,, -OSO3H, -OPO3H, =O, =S, =N-OH, =CH,, a spiro ring, an ester, a thioester, a thionoester, a phosphoester, a phosphothioester, a phosphiniester, a sulfite ester, a sulfate ester, an amide, an amino acid, a peptide, an ether, a thioether, acyl, thioacyl, carbonate, carbamate, a thioacetal, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, optionally substituted monosaccharide, optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide or a polymer, or, two adjacent D ring carbons comprise an independently selected acetal, thioacetal, ketal or thioketal moiety,-386- AMENDED SHEET 25.10.2004 or D comprises two 5- or 6-membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, or a metabolic precursor ora biologically active metabolite thereof, provided that 1, 2 or 3 R" at the 1, 4, 6, 8, 9, 12 and 14 positions are not hydrogen and one or more of the following structural features are present:(a) R™ at the 1-position is -OH, -OR™, =0, -SH, -SR™, =8, -N(R™),, -N3, =NOH, -0-Si-(R")s, -SCN, -NO,, -OSO3H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and one R* is or both R* independently are a halogen, -SH, -SR™, =S, -SCN, thioether, -S-C(O)-optionally substituted alkyl, -N(R™),, -N3, =NOH, -NO,, -NH-C(O)-optionally substituted alkyl or - NH-C(O)-O-optionally substituted alkyl; or (b) R™ at the 1-position is -OH, -OR™, =0, -SH, -SR™, =S, -N(R™®),, -N3, =NOH, -0-Si-(R"®)s, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, halogen, ester,~ thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester,sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and one R? is or both R? independently are -SH, -SRPR, =S, -SCN, thioether, -S-C(O)-optionally substituted alkyl, - N(R™®),, -N3, =NOH, -NO,, -NH-C(O)-optionally substituted alkyl or -NH-C(O)-O- optionally substituted alkyl; or(c) R" at the 1-position is -OH, -OR™, =0, -SH, -SR™, =S, -N(R™),, -N;, =NOH, -0-8i-(R"),, -SCN, -NO,, -OSO;H, -OPO3H, -CHO, -CHS, -CH=NH, -CN, halogen, ester,: thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, substituted . alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and -387- . AMENDED SHEET 25.10.2004 one RZ is or both R? independently are -OH, -OR™, =O, -SH, -SR™®, =S, - N(RR),, -N3, =NOH, -O-Si~(R")3, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, ~ phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer, and one R®is or both R® independently are -OH, -OR™, =0, -SH, -SRR, =§, - N(R), -N3, =NOH, -O-Si-(R")s, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted oligosaccharide or a polymer, and one R* is or both R* independently are -OH, -OR™®, =O, -SH, -SR™®, =§, - N(R"®),, -N5, =NOH, -O-Si-(R*);, -SCN, -NO,, -OSO;H, -OPO;H, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer; or (d) R™ at the 1-position is -OH, -ORFR, =0, -SH, -SR™, =, -N(R™),, -N3, =NOH, : -0-Si-(R")3, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, -Cl, -Br, -I, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and one R®is or both R® independently are -OH, -OR™R, =O, -SH, -SR™®, =§, - N(R™®),, -N3, =NOH, -O-Si~(R"®)5, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, substituted monosaccharide, optionally substituted oligosaccharide or a polymer, one R*is or both R* independently are -OH, -OR™, =O, -SH, -SRR, =S, - N(R™),, -N3, =NOH, -O-Si-(R"),, -SCN, -NO,, -OSO3H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, -388- AMENDED SHEET 25.10.2004 phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide or a polymer; andR® is -O-, -S-, -NH-, -CHSH-, -CHSR™:-, -C(S)-, -CHN(R™),-, -CHN;-, ~-C(NOH)-, -CH(O-Si-(R")3)-, -CH(SCN)-, -CH(NO,)-, -CH(OSO;H)-, -CH(OPO;H)-, -CH(CHO), - CH(CHS), -CH(CH=NH})-, -CH(CN)-, -CH(thioester)-, -CH(thionoester)-, - CH(phosphoester)-, -CH(phosphothioester)-, -CH(phosphonoester)-, - CH(phosphiniester)-, -CH(sulfite ester), -CH(sulfate ester)-, -CH(amino acid)-, - CH(peptide)-, -CH(thioether)-, -CH(N-C(O)-O-optionally substituted alkyl)-, -CH(N-C(O)- O-optionally substituted alkenyl)-, -CH(N-C(O)-O-optionally substituted alkynyl)-, - CH(optionally substituted monosaccharide)-, -CH(optionally substituted oligosaccharide)-, -CH(polymer)-; -C(R"),-C(R")-, -O-C(R")-, -S-C(R").-, -NR""- C(R").-, or R® is absent, leaving a 5-membered ring;(e) R™ at the 6-position is -OH, -OR™, =0, -SH, -SR™, =S, -N(R™),, -N3, =NOH, -0-Si-(R")s, -SCN, -NO,, -OSO3H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle,one Ris or both R® independently are -SH, -SR™, =S, -NHR™, -N;, =NOH, - SCN, -NO,, -NH-C(O)-optionally substituted alkyl or -NH-C(O)-O-optionally substituted alkyl, thioether, and one R* is or both R* independently are -OH, -OR™?, =0, -SH, -SR™, =§, - N(R™),, -N3, =NOH, -O-8i-(R"™)s, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH,-CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted heteroaryl; or(f) R" at the 6-position is -H, -OH, -OR™, =0, -SH, -SR™®, =8, -N(R™®),, -N3, =NOH, -O-Si-(R")3, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester,-389- AMENDED SHEET 25.10.2004 phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle,one R' is or both R' independently are -OH, -OR™®, -SH, -SR™, =8, -N(R™),, - Ns, =NOH, -O-Si-(R")s, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and one R? is or both R? independently are -SH, -SR™, =S, -NHR™, -Nj, =NOH, - SCN, -NO,, -NH-C(O)-optionally substituted alkyl or -NH-C(O)-O-optionally substituted alkyl, thioether, and one R* is or both R* independently are -OH, -OR™, =O, -SH, -SR™, =S, - N(RPR),, -N3, =NOH, -0-Si-(R")5, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, . phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle; or(9) R™ at the 6-position is -OH, -OR™, =0, -SH, -SRR, =S, -N(R™®),, -N;, =NOH, -0-Si-(R™);, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and R’ is -O-, -NR™®-, -S-, -C(R"%),-C(R"),-, -C(R").-C(R"®),-C(R"%),-, -C(R'%),-O- C(R"),-, -C(R"),-S-C(R"),-, -C(R"*),-NR™-C(R°),-, -O-C(R"%),-, -S-C(R"),- or -NRR- C(R")-;-390- AMENDED SHEET 25.10.2004(h) R™ at the 6-position is -OH, -OR™?, =0, -SH, -SR™;, =S, -N(R™),, -N3, =NOH, -0-Si-(R")3, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, -F, -Br, -I, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and Ris -O-, -NR™., -8-, -C(R"%),-C(R"),-, -O-C(R%),-, -S-C(R").-, -NR™R-C(R"°),- or R® is absent, leaving a 5-membered ring; or(i) R" at the 6-position is -OH, -OR™, =0, -SH, -SR™, =S, -N(R™),, -N3, =NOH, - O-Si-(R"®)3, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, -F, -Br, -I,ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and R® is -NR™®-, -S-, -C(R"),-C(R"°),-, -O-C(R")z-, -S-C(R"),-, -NR™-C(R"),- or R® is absent, leaving a 5-membered ring; or(i) R' at the 6-position is -OH, -OR™, =0, -SH, -SR™}, =S, -N(RPR),, -N;, =NOH, - O-Si-(R™)s, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, -F, -Br, I, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle,one R'is or both R' independently are -OH, -ORPR, -SH, -SRR, =§, -N(R),, - Ns, =NOH, -0-Si-(R")s, -SCN, -NO,, -OSO;H, -OPO;H, -CHO, -CHS, -CH=NH, -CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, andR® is -O-; or-391- AMENDED SHEET 25.10.2004(k) R' at the 12-position is -OH, -OR™®, =0, -SH, -SR™R, =S, - N(RPR),, -N3, =NOH, -0-Si-(R")s, -SCN, -NO,, -0SO3H, -OPO;H, -CHO, - CHS, -CH=NH, -CN, halogen, ester, thioester, thionoester, phosphoester, phosphothioester, phosphonoester, phosphiniester, sulfite ester, sulfate ester, amino acid, peptide, amide, ether, thioether, carbonate, carbamate, optionally substituted monosaccharide, optionally substituted oligosaccharide, a polymer, acyl, thioacyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle, and one R? is or both R? independently are -SH, -SR™, =S, -N(R™),, - N3, =NOH, -0O-Si-(R"%)3, -SCN, -NO,, -S-C(O)-optionally substituted alkyl, thioether, -N-C(O)-optionally substituted alkyl or -N-C(O)-O-optionally substituted alkyl, or one R® is or both R® independently are -SH, -SR™, =S, -N(RPR),, - Na, =NOH, -O-Si-(R"®)s, -SCN, -NO, -S-C(O)-optionally substituted alkyl, thioether, -N-C(O)-optionally substituted alkyl or -N-C(O)-O-optionally substituted alkyl, or one R* is or both R* independently are -SH, -SR™, =S, -N(RPR),, -Ns, =NOH, -0-Si-(R")3, -SCN, -NO,, -S-C(O)-optionally substituted alkyl, thioether, - N-C(O)-optionally substituted alkyl or -N-C(O)-O-optionally substituted alkyl.48. A formulation comprising one or more excipients and a compound of claim } 47, wherein the formulation optionally is a sterile parenteral liquid formulation, an oral formulation, a buccal formulation, a sublingual formulation or an aerosol formulation. -392- AMENDED SHEET 25.10.2004
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27262401P | 2001-03-01 | 2001-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200306638B true ZA200306638B (en) | 2004-08-26 |
Family
ID=34078836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200306638A ZA200306638B (en) | 2001-03-01 | 2002-03-01 | Use of certain steroids for treatment of blood cell deficiencies. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200306638B (en) |
-
2002
- 2002-03-01 ZA ZA200306638A patent/ZA200306638B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005330504B2 (en) | Steroid analogs and characterization and treatment methods | |
AU2003278744B2 (en) | Therapeutic treatment methods | |
AU2008201188B2 (en) | Use of certain steroids for treatment of blood cell deficiencies | |
AU2008255138B2 (en) | Therapeutic treatments for blood cell deficiencies | |
US7482334B2 (en) | Therapeutic treatment methods | |
US5763433A (en) | Pharmaceutical compositions containing 3-beta-hydroxylated 6,7-substituted steroid derivatives, and use thereof | |
US9102702B2 (en) | Steroids having 7-oxygen and 17-heteroaryl substitution-2 | |
EP2026818B1 (en) | Combination of steroids having transporter-enhanced corticosteroid activity | |
ZA200306638B (en) | Use of certain steroids for treatment of blood cell deficiencies. |